PROK vs. PRME, NVAX, ALLO, VALN, EXAI, HLVX, CABA, FATE, ALEC, and MESO
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Prime Medicine (PRME), Novavax (NVAX), Allogene Therapeutics (ALLO), Valneva (VALN), Exscientia (EXAI), HilleVax (HLVX), Cabaletta Bio (CABA), Fate Therapeutics (FATE), Alector (ALEC), and Mesoblast (MESO). These companies are all part of the "biological products, except diagnostic" industry.
Prime Medicine (NYSE:PRME) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Prime Medicine received 3 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 69.23% of users gave Prime Medicine an outperform vote while only 66.67% of users gave ProKidney an outperform vote.
ProKidney is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
Prime Medicine's return on equity of 0.00% beat ProKidney's return on equity.
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 24.3% of Prime Medicine shares are held by company insiders. Comparatively, 45.0% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Prime Medicine had 4 more articles in the media than ProKidney. MarketBeat recorded 13 mentions for Prime Medicine and 9 mentions for ProKidney. Prime Medicine's average media sentiment score of 0.48 beat ProKidney's score of 0.32 indicating that ProKidney is being referred to more favorably in the news media.
Prime Medicine has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
Prime Medicine presently has a consensus target price of $16.89, indicating a potential upside of 277.83%. ProKidney has a consensus target price of $9.50, indicating a potential upside of 300.84%. Given Prime Medicine's higher possible upside, analysts clearly believe ProKidney is more favorable than Prime Medicine.
Summary
Prime Medicine beats ProKidney on 8 of the 15 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
